- Home
- Partnership
- Whom do we partner with?
A strong track record of partnerships
Today, more than half of LEO Pharma’s portfolio is developed together with partners. Our current partnerships span across many different areas, from large pharmaceutical companies, to academia and contract research organizations.
Selection of our ongoing partnerships:
Gilead
In 2025, LEO Pharma entered into a strategic partnership with Gilead Inc. to advance LEO Pharma’s small molecule STAT6-program. LEO Pharma retains the rights for the topical program in dermatological disease, whilst Gilead will accelerate the development of the STAT6-program in oral formulation. LEO Pharma retains the option to co-commercialise the oral program outside the United States.
Boehringer Ingelheim
In 2025, LEO Pharma and Boehringer Ingelheim formed a strategic partnership granting LEO Pharma exclusive rights to develop and commercialize a treatment for rare dermatological diseases. LEO Pharma’s six decades of dermatology expertise will be instrumental to broaden access to treatment for patients while advancing the standard of care for people living with skin conditions.
